Hair loss clinical trials recruiting in France
5 recruiting studies in alopecia with at least one site in France, from ClinicalTrials.gov: phase, sponsor, and the programme in the register each one belongs to. Refreshed nightly.
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer · Target enrolment: 140 · Sep 2025 · United States, China, Czechia, France
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AbbVie · Target enrolment: 2795 · Sep 2025 · Argentina, Canada, Colombia, Czechia
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie · Target enrolment: 1500 · Oct 2023 · United States, Argentina, Australia, Belgium
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company · Target enrolment: 595 · Feb 2023 · United States, Argentina, Australia, Canada
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
University Hospital, Bordeaux · Target enrolment: 450 · Jan 2020 · France
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.